NCT06541457View on ClinicalTrials.gov

A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions

Hyperlipidemia

Interventions

DRUG

HRS-7249 injection

6 subjects for HRS-7249 injection

DRUG

Placebo

2 subjects for placebo

Trial Locations (1)

310009

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06541457 - A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter